Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 3/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | CPS1 | P31327 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19987447 | 0.86 | KIF11 (0.48) | KIF11CYP11B1CYP11B2CYP1A1CYP1A2 | |
| SCHEMBL19987569 | 0.85 | NQO1 (0.41) | KIF11CYP1A2CPS1ALDH1A1 | |
| SCHEMBL19987506 | 0.84 | PDE2A (0.43) | KIF11 | |
| SCHEMBL10686133 | 0.82 | KIF11 (0.49) | KIF11CYP11B1CYP11B2CYP1A1CYP1A2 | |
| SCHEMBL21139206 | 0.82 | EPHX2 (0.41) | KIF11CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL8507684 | 0.80 | KIF11 (0.52) | KIF11CYP11B1CYP11B2CYP1A1CYP1A2 | |
| SCHEMBL18649480 | 0.79 | RIPK1 (0.39) | CYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL1506600 | 0.78 | KIF11 (0.49) | KIF11CYP11B1CYP11B2CYP1A1CYP1A2 | |
| SCHEMBL11786492 | 0.77 | GAA (0.50) | ALDH1A1 | |
| SCHEMBL19232083 | 0.76 | HDAC3 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | IDO1, IDO2, INMT | KIF11 3776/4885CYP11B1 273/4885CYP11B2 246/4885 |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | KIF11 3776/4885CYP11B1 273/4885CYP11B2 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.